Literature DB >> 16782539

The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo.

Zhang Linghua1, Tian Xingshan, Zhou Fengzhen.   

Abstract

Oligodinucleotides containing CpG motifs (CpG ODN) are strong adjuvants for immune responses, particularly in mice, the immunostimulatory effects of CpG in combination with aluminum hydroxide (alum) or Emulsigen (Em) were investigated in cattle, rabbits or mice, but not piglets. In this report, using the swine streptococcus as model bacteria, the efficacy of CpG ODN as an adjuvant for piglets was assessed alone and in combination with alum (CpG/alum) or Em (CpG/Em). The CpG/alum or CpG/Em combination elicited greater immune responses to swine streptococcic septicemia killed vaccine (SSSK vaccine) compared with CpG alone, or alum or Em. A GpC/alum or GpC/Em combination did not have the same effects as CpG/alum or CpG/Em suggesting that the adjuvanticity was related to the CpG motifs. In addition, we also found that the 10% Em in combination with CpG ODN had similar immunological effects as 30% Em combination. Our results demonstrate that the addition of CpG ODN to alum or to Em significantly improves the efficiency of the adjuvants in piglets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782539     DOI: 10.1016/j.intimp.2006.03.009

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Authors:  Catpagavalli Asokanathan; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

2.  Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Patricia Garcia; Erin Jenkins; Pamela J Glass; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

3.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

4.  Porcine Dendritic Cells as an In Vitro Model to Assess the Immunological Behaviour of Streptococcus suis Subunit Vaccine Formulations and the Polarizing Effect of Adjuvants.

Authors:  Léa Martelet; Sonia Lacouture; Guillaume Goyette-Desjardins; Guy Beauchamp; Charles Surprenant; Marcelo Gottschalk; Mariela Segura
Journal:  Pathogens       Date:  2017-03-22

5.  LACpG10-HL Functions Effectively in Antibiotic-Free and Healthy Husbandry by Improving the Innate Immunity.

Authors:  Weixiong Pan; Zengjue Zhao; Jiahui Wu; Qin Fan; Haobin Huang; Rongxiao He; Haokun Shen; Zitong Zhao; Saixiang Feng; Guanhua Gan; Zhiyang Chen; Miaopeng Ma; Chongjun Sun; Linghua Zhang
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

6.  TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.

Authors:  Rasmus Offersen; Jesper Melchjorsen; Søren R Paludan; Lars Østergaard; Martin Tolstrup; Ole S Søgaard
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.